Analysis Tools
hematopoietic system
|
• leukocyte counts in peripheral blood from transgenic mice increase progressively over time, and they rise dramatically after 30 weeks; flow cytometric analysis reveals most of the increase to be in the CD8+ T cell population
• when transgenic mice have become symptomatic, histologic examination reveals infiltration and perivascular accumulation of lymphocytes in nonlymphoid organs
|
|
• by the time transgenic mice become symptomatic, their spleens and lymph nodes are greatly (often 10-fold) enlarged and the organs' structure and integrity have been disrupted due to heavy lymphocyte infiltration
|
|
• by between 6 and 12 weeks of age, the memory T cell suface markers CD44 and interleukin-2 receptor beta (IL-2Rb) become greatly elevated on transgenic CD8+ T cells, and by 12 weeks the levels are greater than in 60 week old wild-type mice; levels of CD25, CD62L, CD69 and CD45Rb are generally unaffected, as are surface markers of CD4+ T cells
|
immune system
|
• leukocyte counts in peripheral blood from transgenic mice increase progressively over time, and they rise dramatically after 30 weeks; flow cytometric analysis reveals most of the increase to be in the CD8+ T cell population
• when transgenic mice have become symptomatic, histologic examination reveals infiltration and perivascular accumulation of lymphocytes in nonlymphoid organs
|
|
• by the time transgenic mice become symptomatic, their spleens and lymph nodes are greatly (often 10-fold) enlarged and the organs' structure and integrity have been disrupted due to heavy lymphocyte infiltration
|
|
• by between 6 and 12 weeks of age, the memory T cell suface markers CD44 and interleukin-2 receptor beta (IL-2Rb) become greatly elevated on transgenic CD8+ T cells, and by 12 weeks the levels are greater than in 60 week old wild-type mice; levels of CD25, CD62L, CD69 and CD45Rb are generally unaffected, as are surface markers of CD4+ T cells
|
behavior/neurological
|
• late in disease progression, transgenic mice become lethargic; homozygous mice become symptomatic approximately 4 months earlier than mice hemizygous for the transgene
|
growth/size/body
|
• late in disease progression, transgenic mice exhibit weight loss; homozygous mice become symptomatic approximately 4 months earlier than mice hemizygous for the transgene
|
respiratory system
|
• late in disease progression, transgenic mice exhibit breathing difficulty; homozygous mice become symptomatic approximately 4 months earlier than mice hemizygous for the transgene
|
neoplasm
|
• by the time transgenic mice become symptomatic, their spleens and lymph nodes are greatly (often 10-fold) enlarged and the organs' structure and integrity have been disrupted due to heavy lymphocyte infiltration
|
|
• progression to leukemia is associated with clonal expansion of CD8+ T cells, evidenced by a single predominant T cell receptor beta (TCR-Vb) rearrangement in the expanded CD8+ T cell population of every transgenic mouse with histologically confirmed leukemia; specific rearrangements differ among individual mice
|
cellular
|
• leukocyte counts in peripheral blood from transgenic mice increase progressively over time, and they rise dramatically after 30 weeks; flow cytometric analysis reveals most of the increase to be in the CD8+ T cell population
• when transgenic mice have become symptomatic, histologic examination reveals infiltration and perivascular accumulation of lymphocytes in nonlymphoid organs
|
endocrine/exocrine glands
|
• by the time transgenic mice become symptomatic, their spleens and lymph nodes are greatly (often 10-fold) enlarged and the organs' structure and integrity have been disrupted due to heavy lymphocyte infiltration
|
